From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Characteristic | Escalating (n = 43) | Not escalating (n = 46) | P value |
---|---|---|---|
Female, n (%) | 37 (86.0) | 41 (89.0) | 0.753 |
Age, median (IQR) | 50 (41–56) | 47 (38–51) | 0.122 |
Years of migraine history, median (IQR) | 30 (20–36) | 26.5 (18–37) | 0.436 |
MMDs, median (IQR) | 25 (17.5–30) | 17 (11–25) | 0.002 |
Analgesic days, median (IQR) | 10 (5–28) | 12 (5–19) | 0.485 |
Triptan days, median (IQR) | 6 (0–20) | 0 (0–12) | 0.172 |
Chronic migraine, n (%) | 40 (93.0) | 44 (95.7) | 0.670 |
Aura, n (%) | 12 (27.9) | 15 (32.6) | 0.651 |
Allodynia, n (%) | 16 (37.2) | 17 (37.0) | 0.456 |
Medication overuse, n (%) | 35 (81.4) | 29 (63.0) | 0.054 |
Prior preventive treatment failures, n (%) | Â | Â | 0.501 |
 2 | 15 (34.9) | 13 (28.3) |  |
 > 2 | 28 (65.1) | 33 (71.7) |  |
Botulinum toxin failure, n (%) | 22 (51.2) | 22 (47.8) | 0.753 |